Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Cs Capital

BioCentury | Aug 10, 2023
Finance

Aug. 9 Quick Takes: Alltrna raises $109M for unified approach to stop codon diseases

Plus: Venture cash for ADARx, Georgiamune, Neurophth and updates from Regeneron-Decibel, Novartis, Sunbird-Glympse, Denali-Takeda and more
BioCentury | Aug 23, 2022
Regulation

Aug. 23 Quick Takes: Clinical hold sinks Foghorn

Plus Third Harmonic consider IPO, eTheRNA raises €39M and updates from Gate, Freedom and more
BioCentury | May 19, 2022
Product Development

May 18 Quick Takes: Enanta tumbles after hours after missing RSV endpoint

Plus: House E&C passes user fee bill and updates from Hengrui, Laekna, Prenetics, Enanta and more
BioCentury | Mar 10, 2022
Product Development

March 9 Quick Takes: Pfizer and Sobi’s factor VIII therapy meets Phase III endpoints

Plus Adaptive retools, adds CFO, and updates from InxMed, Bayer, Twist-Kriya and more
BioCentury | Mar 5, 2012
Company News

Eleison board of directors update

BioCentury | Mar 5, 2012
Financial News

Eleison completes venture financing

Items per page:
1 - 6 of 6